OUTSOURCED PHARMA CAPACITY UPDATE SMALL MOLECULE VIDEOS
Upperton Pharma Solutions Capabilities Update April 2026: Small Molecule Drug Product
Learn more about UK-CDMO, Upperton Pharma Solutions, and their expertise across oral, nasal, pulmonary and sterile drug product development and manufacturing
Thermo Fisher Scientific Capabilities Update April 2026: Small Molecule Drug Product
Align formulation, process, and scale strategy early to support larger batches, new equipment, and commercial manufacturing — cutting rework and speeding Phase I to launch.
Douglas CDMO Capabilities Update April 2026: Small Molecule Drug Product
Douglas CDMO assists pharmaceutical and biotechnology companies with their contract manufacturing and development needs, specializing in high-potency softgels and liquids.
Bora Pharmaceuticals Capabilities Update April 2026: Small Molecule Drug Product
Bora Pharmaceuticals is a global CDMO specializing in small molecule drug product development and manufacturing from clinical through commercial supply.
Adare Pharma Solutions Capabilities Update April 2026: Small Molecule Drug Product
With a proven history in drug delivery, Adare’s facilities in the US and Europe have developed and manufactured more than 65 products sold by customers worldwide.
Quotient Sciences Capabilities Update March 2026: Small Molecule Drug Product
This session is designed to help you assess which development approaches, locations, and timelines may be most appropriate for your asset.
Pfizer CentreOne Capabilities Update March 2026: Small Molecule Drug Product
From development through commercial supply, our integrated capabilities and rigorous quality standards ensure reliable execution and consistent performance at every stage.
PCI Pharma Services Capabilities Update March 2026: Small Molecule Drug Product
Gain insight into our SMART FHD™ approach, designed to accelerate early-phase development through streamlined first-human-dose readiness, as well as its integrated partner network for targeted protein degraders (TPDs).
Mikart Capabilities Update March 2026: Small Molecule Drug Product
Discover how integrated formulation development, scalable manufacturing, and robust facility infrastructure can streamline your small molecule programs from early development through commercial production with confidence.
Asymchem Capabilities Update March 2026: Small Molecule Drug Product
Guided by a technology-driven approach and supported by a highly coordinated development and manufacturing ecosystem, we provide high-quality, efficient drug product solutions aligned with stringent global regulatory standards.
SK Pharmteco Capabilities Update March 2026: Small Molecule Drug Substance
Join Frank Mueller, Executive Director of Business Development, for an overview of our capabilities and global capacity spanning North America, Europe, and Asia.
Novartis Capabilities Update March 2026: Small Molecule Drug Substance
Driven by a strong commitment to quality, compliance, and operational excellence, our teams deliver reliable and scalable manufacturing solutions tailored to each partner’s unique requirements.
Ropack Pharma Solutions Capacity Update October 2025: Small Molecule
For clinical trials, we provide full support from warehousing to returns. Join Ropack's Head of Commercial, Chris Vounasis, for a presentation on our technologies and 2025–2026 capacity.
Pfizer CentreOne Oral Solids Capacity Update October 2025: Small Molecule
With specialized technologies like laser drilling, multilayer coating, and orally disintegrating tablets, our state-of-the-art facilities provide the precise infrastructure to support your most demanding OSD requirements.
Lonza Capacity Update October 2025: Small Molecule
Get an overview of our AI-assisted early phase toolkit, which combines predictive modeling, formulation screening, and data-driven insights to accelerate molecule progression.
Douglas CDMO Capacity Update October 2025: Small Molecule
Choose an experienced CDMO specializing in high-potency softgels and liquids to ensure high-quality products, responsive service, and reliable solutions across complex therapeutic areas.
Alcami Capacity Update October 2025: Small Molecule
Partner with a flexible, high-quality manufacturing expert to accelerate your bench-to-clinic journey, strengthen supply chain, and ensure seamless commercialization of oral solid dose therapies.
Upperton Pharma Solutions Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form
Ian Lafferty, CTO, and Josh Moule, Business Development Manager, talk through Upperton’s capabilities, project management approach and provide a virtual tour of their 60,000 sq. ft development and manufacturing facility.
Quotient Sciences Capacity Update July 2025
Explore how expedited review pathways can be strategically used to accelerate development while mitigating CMC risks.
PCI Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form
Dr. Rebecca Coutts highlights PCI’s high potent oral solid dose (OSD) and oral liquid capabilities, focusing on site expertise, specialized infrastructure, and handling of complex molecules.
Agenda & Presenter Details
Visit our registration pages to see the current agenda and our list of presenting sponsors.
How can we help?
Are you a supplier looking to present at our next event?